Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 8/20 | 0.43 |
| ▸ | RXRB | P28702 | 8/20 | 0.43 |
| ▸ | RXRG | P48443 | 8/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409657 | 0.90 | RXRA (0.41) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409643 | 0.85 | HTR6 (0.54) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409639 | 0.83 | GPR84 (0.52) | RXRARXRBRXRGNR4A2GPR84 | |
| SCHEMBL18409637 | 0.80 | CDK4 (0.46) | HTR6RXRARXRBRXRGGPR84 | |
| SCHEMBL22692981 | 0.77 | NR4A2 (0.46) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409642 | 0.77 | NR4A2 (0.53) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409339 | 0.75 | HTR6 (0.52) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409633 | 0.75 | PTPN1 (0.45) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409641 | 0.74 | CDK4 (0.47) | HTR6RXRARXRBRXRGGPR84 | |
| SCHEMBL18409723 | 0.74 | RXRA (0.54) | HTR6RXRARXRBRXRGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017011920-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-01-26 | — | — | WO | disclosed |